SECOND AMENDMENT TO LICENSE AGREEMENT

SECOND AMENDMENT TO LICENSE AGREEMENT

This Second Amendment to License Agreement (“Second Amendment”) is effective December 31, 2018 (“Effective Date”), by and between: Cytocom Inc., a for profit corporation duly organized and existing under the laws of the Commonwealth of Delaware, having an office at 00 Xxxxx Xxxxxx Xxx Xxxxx 000 Xxxxxxx Xxxxxxx 00000 (“CYTO”), and Immune Therapeutics Inc., a Florida Corporation formerly doing business as TNI BioTech, Inc., having an office at 0000 Xxxxx Xxx #000 Xxxxxx Xxxx, XX 00000 (“IMUN and or Company or Licensee”). CYTO and Licensee may each be referred to individually as “Party” and collectively as “Parties”.

WITNESSETH

WHEREAS, the Parties entered into that certain Amended License Agreement, effective May 1, 2018 (the “License Agreement”); and

WHERAS, as a consequence of the License Agreement, the Company deconsolidated CYTO as of May 1, 2018 in its financial reporting, and now accounts for its retained interest in CYTO under the equity method of accounting;

WHERAS, as a consequence of the deconsolidation of CYTO in the Company’s financial reporting, the Parties wish to clarify and confirm which obligations of the Parties incurred by either Party before the Effective Date will become the sole obligations of CYTO on and after the Effective Date;

WHEREAS, the Parties desire to further amend the License Agreement to provide for the assumption of additional obligations of CYTO by IMUN as consideration for the agreement that China will be included as a Territory under the License Agreement;

NOW THEREFORE, in consideration of the foregoing and the mutual promises and covenants set forth herein and for good and valuable consideration, the adequacy and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

1.       Definitions. For purposes of this Second Amendment, all capitalized terms shall have the meaning ascribed by the License Agreement unless expressly amended herein.

1.1       “Territory” means, all countries listed in the License Agreement signed May 1, 2018, together with the Republic of China.

1.2       “Accounts Payable “means those accounts payable obligations and accrued liabilities as specified in Schedule 1 “Cytocom Inc. Accounts Payable and Accrued Obligations” attached hereto.

1.6       “Notes Payable” means those obligations owed under certain promissory notes as specified in Schedule 2 “Cytocom Inc. Notes Payable” hereto.

2.       Confirmation of Ownership of Cytocom Inc, by Company. The Parties confirm and agree that in accordance with the Stock Purchase Agreement signed by the Parties on June 4, 2018, as of the Effective Date IMUN owns common stock of CYTO representing 15.57% of the outstanding common shares of CYTO as of the Effective Date, and that, in the event that CYTO issues additional shares after the Effective Date and up to and including the completion of a Series A round in an amount greater than $3 million, or IPO, or Sale of CYTO, CYTO will cause additional shares to be issued to IMUN in such number that IMUN’s percentage of outstanding common stock will not fall below 15.57%.

Page 1 of 5

3.       Assumption of Accounts Payable. The Parties agree that IMUN shall assume the obligation to repay all accounts payable obligations and accrued liabilities owed by CYTO as of the Effective Date, except those accounts payable obligations and accrued liabilities as specified in Schedule 1 “Cytocom Inc. Accounts Payable and Accrued Obligations” attached hereto, which shall continue to be obligations of CYTO on and after the date of this Second Amendment.

4.       Assumption of Notes Payable. The Parties agree that IMUN shall assume the obligation to repay all notes payable, together with any interest or fees payable thereon, owed by CYTO as of the Effective Date, except those notes payable obligations, together with any interest or fees payable thereon, as specified in Schedule 2 “Cytocom Inc. Notes Payable” attached hereto, which shall continue to be obligations of CYTO on and after the date of this Second Amendment.

5.        Buyout. In the event of a Change of Control of CYTO, and at the option of CYTO, the Company shall have the right to purchase outright the Company’s licensing rights to Emerging Markets for humans under the License Agreement at a price equal to the value of those licensing rights as determined by an independent valuator acceptable to the Company and CYTO, which determination shall be final and binding. The cost of said valuation will be paid for by CYTO.

6.       Interpretation. Except to the extent specifically amended by this Second Amendment, all terms and conditions set forth in the License Agreement shall remain unchanged and in full force and effect.

7.       Entire Agreement. This Second Amendment, in conjunction with the License Agreement, constitutes the entire agreement between the Parties regarding the subject matter hereof and supersedes any prior understandings, agreements or representations between the Parties, written or oral, relating to the subject matter hereof.

8.       Counterparts. This Second Amendment may be executed in any number of counterparts, each of which shall be deemed to be an original as against a Party whose signature appears thereon, and each of which shall together constitute one and the same instrument. Any counterpart signature page delivered by electronic means or by facsimile transmission shall be deemed to have the same force and effect as an originally executed signature page.

[SIGNATURES APPEAR ON FOLLOWING PAGE]

Page 2 of 5

IN WITNESS WHEREOF, the Parties, intending to be legally bound hereby, have each caused a duly authorized representative to execute this Second Amendment on the day and year set forth below.

LICENSEE:
Immune Therapeutics, Inc.
By:
Name	Xxxxxx Xxxxxxx
Title:	Chief Executive Officer
Date:	April 8, 2019
LICENSOR:
Cytocom, Inc.
By:
Name:	Xxxxxx Xxxxxxx
Title:	President
Date:	April 8, 2019

Page 3 of 5

Schedule 1

Cytocom Inc. Accounts Payable and Accrued Obligations

Vendors and Accounts Payable		Amount ($)
LDN Research Group LLC		$	74,670.00
Xxxxx XxXxxx Xxxxxxxx			37,500.00
Dr. Xxxx Xxxxx			24,669.98
Xxxxxxxx Management Services Inc			24,000.00
Birch Xxxxxxx Xxxxxx Xxxxx LLP			20,569.76
Xxxxxx Management Services Inc			16,666.67
The Pennsylvania State University			8,747.41
Husch Xxxxxxxxx LLP			4,586.70
ClearTrust, LLC			750.00
Corporate Creations			561.85
Xx. Xxxxxxxx X. Xxxxx Esq.			(500.00	)
TOTAL		$	212,222.37

Creditors and Accrued Liabilities		Amount ($)
Xxxxxx Xxxxxxx		$	520,000.00
Xxxxx Xxxxxx			32,000.00
Xxxxxx Xxxxxx			32,000.00
TOTAL		$	584,000.00

Page 4 of 5

Schedule 1

Cytocom Inc. Notes Payable

Borrower at Date of Note Signing		Effective Date of Note		Lender		Principal Amount of Note ($)				Maturity Date		Accrued Interest and Fees at 12/31/20118 ($)				Total Owing at 12/31/2018 ($)
Cytocom		6/16/2015		MJW Properties		$	25,000.00			9/30/2015		$	3,775.00			$	28,775.00
Cytocom		9/30/2015		Xxxxxxx Xxxxxxxxx			400,000.00			9/30/2016			104,153.42				504,153.42
Xxxxxxx		0/0/0000		XX Xxxxxx			80,000.00			1/8/2017			23,846.58				103,846.58
Cytocom		2/8/2016		Xxxx Xxxx			50,000.00			2/8/2017			14,479.45				64,479.45
Immune		3/9/2016		Xxxx Xxxx			20,000.00			3/8/2017			5,705.56				25,705.56
Immune		4/11/2016		P Akin-QS			21,000.00			4/11/2017			5,798.33				26,798.33
Immune		9/30/2016		Xxxx Xxxx			20,000.00			9/30/2017			1,959.00				21,959.00
Immune		9/30/2016		Xxxx Xxxx			25,000.00			9/30/2017			2,448.75				27,448.75
Immune		9/30/2016		Xxxx Xxxx			33,000.00			9/30/2017			3,232.35				36,232.35
Immune		9/30/2016		Xxxx Xxxx			6,000.00			9/30/2017			587.70				6,587.70
Immune		10/7/2016		Xxxx Xxxx			10,000.00			10/7/2017			975.42				10,975.42
Immune		11/1/2016		Xxxxxxx Xxxxxxxxx			275,000.00			11/1/2017			26,422.92				301,422.92
Xxxxxx		00/0/0000		XX Xxxxxx			275,000.00			11/1/2017			26,422.92				301,422.92
Immune		12/31/2016		Xxxxxxx Xxxxxxxxx			30,000.00			2/18/1982			2,777.50				32,777.50
Immune		3/31/2017		XX Xxxxxx			165,000.00			3/31/2018			14,410.00				179,410.00
Immune		3/31/2017		Xxxx Xxxx			5,000.00			3/31/2018			436.67				5,436.67
Xxxxxx		0/0/0000		XX Xxxxxx			150,000.00			4/3/2018			13,073.75				163,073.75
Immune		9/30/2017		Xxxx Xxxx			25,000.00			9/30/2018			1,916.46				26,916.46
Cytocom		3/31/2018		Xxxxx Xxxxxxx			50,000.00			3/31/2019			1,909.72				51,909.72
Cytocom		3/31/2018		Xxxxxxx Xxxxxxxxx			101,000.00			3/31/2019			3,857.64				104,857.64
Xxxxxxx		0/00/0000		XX Xxxxxx			70,000.00			3/31/2019			6,307.29				76,307.29
Cytocom		3/31/2018		Xxxxx St Ledger			75,000.00			3/31/2019			2,864.58				77,864.58
Cytocom		5/14/2018		Xxxxx St Ledger			50,000.00			5/14/2019			1,604.17				51,604.17
Cytocom		6/30/2018		Xxxx Xxxx			10,000.00			6/30/2019			255.56				10,255.56
Cytocom		6/30/2018		Xxxxxxx Xxxxxxxxx			37,500.00			6/30/2019			958.33				38,458.33
Xxxxxxx		0/00/0000		XX Xxxxxx			50,000.00			6/30/2019			1,277.78				51,277.78
Cytocom		7/1/2018		Xxxx Xxxxxxxxxx (replace)			83,000.00			7/1/2019			2,080.68				85,080.68
Cytocom		7/13/2018		Xxxx Xxxxxxxxxx			10,000.00			7/13/2019			237.50				10,237.50
Cytocom		8/23/2018		Xxxxxxx Xxxxxx			10,000.00			12/23/2018			575.83				10,575.83
Cytocom		9/30/2018		Xxxxxxx Xxxxxxxxx			62,000.00			9/30/2019			792.22				62,792.22
Xxxxxxx		0/00/0000		XX Xxxxxx			30,000.00			9/30/2019			383.33				30,383.33
TOTAL						$	2,253,500.00					$	275,526.41			$	2,529,026.41

Page 5 of 5